Cytecare Cancer Hospitals has apponited Dr. Hari Menon as senior consultant – haemato-oncology. Dr. Menon has been in the field of medical oncology for nearly two decades, where he has been associated with reputed hospitals like the Tata Memorial Cancer Centre, Mumbai.
His special focus lies in the specialized field of hematological malignancies, which caters to both leukaemia (blood cancers) and lymphomas (malignancies associated with the lymphoid reticular system). His key areas include acute and chronic leukaemia, lymphomas, central nervous system tumours and stem cell therapy.
He has been a member of the ICMR task force for formulating guidelines in haematological malignancies and was the recipient of the ACORD (Australia & Asia Pacific Clinical Oncology Research Development) and INDOX (India Oxford clinical research) training. Additionally, he is also a national faculty for ACORD and CREDO in India which are bodies involved in training researchers and oncologists in the field of clinical research.
Commenting on the appointment, Suresh Ramu, CEO & co founder, Cytecare Hospitals, said that Dr. Menon comes with immense expertise and experience in the field of haemato-oncology and we are happy to have him lead a team of doctors at Cytecare.
Prior to joining Cytecare, Dr. Menon had worked at the Tata Memorial Cancer Centre, Mumbai, as a consultant and Professor of Medical Oncology for the past 12 years. He has been credited with over 50 publications, and numerous presentations and book chapters. He is member of the American society of hematology and the European hematology association. He is a reviewer for Indian and international peer-reviewed oncology journals, and has been an invited member of the advisory board for drug development by several multi-national pharmaceutical companies. Besides he is also associated with cancer patient advocacy and support groups, and with agencies striving to make cancer care widely available to patients.
Dr. Hari Menon said, “Cytecare is focused on improving the quality of cancer care in India and is committed to international standards of research in the field. This is a great opportunity for me to leverage my two decades of experience to push Cytecare’s endeavour in creating a more patient-centric cancer care system.”
